ATE536888T1 - Zusammensetzungen zur mehrstufigen anwendung von hot-spot-bestrahlung auf krebszellen - Google Patents

Zusammensetzungen zur mehrstufigen anwendung von hot-spot-bestrahlung auf krebszellen

Info

Publication number
ATE536888T1
ATE536888T1 AT05802465T AT05802465T ATE536888T1 AT E536888 T1 ATE536888 T1 AT E536888T1 AT 05802465 T AT05802465 T AT 05802465T AT 05802465 T AT05802465 T AT 05802465T AT E536888 T1 ATE536888 T1 AT E536888T1
Authority
AT
Austria
Prior art keywords
compositions
cancer cells
hot spot
step application
spot radiation
Prior art date
Application number
AT05802465T
Other languages
English (en)
Inventor
George Mayers
David Lee
Hsiao-Ling Chin
Original Assignee
Oncologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncologic Inc filed Critical Oncologic Inc
Application granted granted Critical
Publication of ATE536888T1 publication Critical patent/ATE536888T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AT05802465T 2004-07-23 2005-07-25 Zusammensetzungen zur mehrstufigen anwendung von hot-spot-bestrahlung auf krebszellen ATE536888T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/897,530 US7615221B2 (en) 2004-07-23 2004-07-23 Compositions and methods for treating cancer
PCT/US2005/026248 WO2006010165A2 (en) 2004-07-23 2005-07-25 Compositions for multi-step delivery of hot-spots radiation to cancer cells

Publications (1)

Publication Number Publication Date
ATE536888T1 true ATE536888T1 (de) 2011-12-15

Family

ID=35657441

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05802465T ATE536888T1 (de) 2004-07-23 2005-07-25 Zusammensetzungen zur mehrstufigen anwendung von hot-spot-bestrahlung auf krebszellen

Country Status (7)

Country Link
US (1) US7615221B2 (de)
EP (1) EP1809332B1 (de)
JP (1) JP2008507562A (de)
AT (1) ATE536888T1 (de)
AU (1) AU2005265425A1 (de)
CA (1) CA2572825A1 (de)
WO (1) WO2006010165A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5169064B2 (ja) * 2007-08-09 2013-03-27 大日本印刷株式会社 可溶性ポルフィリン誘導体
GB0901483D0 (en) * 2009-01-29 2009-03-11 Ge Healthcare Ltd Radioiodination method
WO2019165171A2 (en) * 2018-02-22 2019-08-29 North Carolina State University Compounds and methods useful in brachytherapy
CN114502171A (zh) * 2019-07-25 2022-05-13 北卡罗莱纳州立大学 交联化合物及其使用方法
EP4054561A4 (de) * 2019-11-08 2023-12-20 North Carolina State University Vernetzende verbindungen und verfahren zur verwendung davon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892817A (en) * 1987-09-21 1990-01-09 Biogenex Laboratories Stable phosphatase substrate composition
US6080383A (en) * 1997-01-13 2000-06-27 Rose; Samuel Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
US7807136B2 (en) 1997-01-13 2010-10-05 David S. Rose Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer
US5816259A (en) 1997-01-13 1998-10-06 Rose; Samuel Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells
WO2002087497A2 (en) 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
JP4896708B2 (ja) 2003-02-05 2012-03-14 ジーイー・ヘルスケア・バイオサイエンス・コーポレイション 新規リンカー類を有する末端リン酸標識ヌクレオチド類

Also Published As

Publication number Publication date
JP2008507562A (ja) 2008-03-13
EP1809332B1 (de) 2011-12-14
WO2006010165A2 (en) 2006-01-26
US7615221B2 (en) 2009-11-10
EP1809332A2 (de) 2007-07-25
WO2006010165A3 (en) 2007-02-08
CA2572825A1 (en) 2006-01-26
AU2005265425A1 (en) 2006-01-26
US20060018908A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
DK2010181T3 (da) Fremgangsmåder til behandling af celleproliferative forstyrrelser under anvendelse af pyrimidindiamin- forbindelser
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
EA201790962A1 (ru) Терапевтические соединения и связанные с ними способы применения
NO20076401L (no) Diarylhydantoinforbindelser
MY159955A (en) Certain chemical entities, compositions and methods
CY1119509T1 (el) Συνθεσεις και μεθοδοι για ρυθμιστες αποπτωσης
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
WO2005107474A3 (en) Oncolytic adenovirus armed with therapeutic genes
EA200901653A1 (ru) ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
NO20081972L (no) Generering og profilering av fulle humane hucal gull-deriverte terapeutiske antistoffer spesifikke for human CD38
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
MY168762A (en) Certain chemical entities, compositions and methods
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
MX2007000606A (es) Arilidenos para el tratamiento de enfermedades mediadas por receptor alfa relacionado con estrogeno.
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
WO2007065010A3 (en) Anti-angiogenesis compounds
ATE536888T1 (de) Zusammensetzungen zur mehrstufigen anwendung von hot-spot-bestrahlung auf krebszellen
ECSP077416A (es) Mimeticuerpos que se unen al receptor de melanocortina, composiciones, metodos y usos
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
WO2009054939A8 (en) Cancer classification and methods of use
BR122018009866B8 (pt) métodos para preparar compostos de éter aminocicloexílico e compostos intermediários
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren